Efficacy Of Ergocalciferol In Adults According To BMI

Obesity Clinical Trial

Official title:

Efficacy Of Ergocalciferol In Adults According To BMI

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02435771
• Other study ID #: 359128-8
• Status: Terminated
• Phase: Phase 4
• First received: May 21, 2013
• Last updated: May 10, 2017
• Start date: July 2011
• Est. completion date: April 2017

Study information

• Verified date: May 2017
• Source: Walter Reed National Military Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Vitamin D insufficiency is an increasing trend in the United States. According to the NHANES data collection there was a near doubling of patients with vitamin D deficiency in 10 years. Vitamin D deficiency is associated with several adverse outcomes such as increased fractures, certain microbial diseases, cardiovascular diseases, and metabolic dysfunction. The increasing prevalence of vitamin D deficiency has been attributed to the increasing prevalence of obesity. Several studies have shown that obese patients have lower 25-OH vitamin D (25-OHD) levels compared to nonobese patients and obese patients require more vitamin D compared to nonobese patients. The most commonly prescribed medication to replete vitamin D deficiency is oral ergocalciferol. To date, no prospective trials have been published to evaluate a standard protocol in the treatment of vitamin D insufficiency in adults.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 44
• Est. completion date: April 2017
• Est. primary completion date: April 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Study subjects have to be between the ages of 18 to 65 with a serum 25OHD level less than 20 ng/ml.

Exclusion Criteria:

• Participants will be excluded if they have any of the following:

1. Due to the inaccuracies of BMI in patients with increased muscle mass, in group with a BMI 25-35: men with a waist circumference < 90 cm ; women < 80 cm

2. Chronic liver disease defined by any clinical or a history of serum AST or ALT > 2 times ULN

3. Kidney disease defined as a GFR <60 ml/min

4. Sarcoidosis

5. Any known malignancy

6. Known malabsorption disorder to include inflammatory bowel disease, celiac disease, cystic fibrosis, history of gastric bypass

7. Primary hyperparathyroidism or hypercalcemia,

8. Patients that are pregnant or considering pregnancy.

9. Patients taking certain medications such as glucocorticoids, anti-seizure medications such has phenobarbital or phenytoin or patients taking antiviral medications for HIV as these are known to cause vitamin D deficiency

10. Individuals excluded from having a DXA scan

Study participants will be excluded from having a DXA scan if any of the following:

1. Any amputation of a extremity including toes

2. If they have a pacemaker, automatic defibrillator, coronary stents or metal suture material in the heart

3. If they have artificial joints, pins, plate or any other type of metal objects

4. If they have received contrast material such as barium in the past 7 days

5. If they have had a nuclear medicine study in the past 3 days

Related Conditions & MeSH terms

• Obesity
• Vitamin D Deficiency

Intervention

Drug:
• Ergocalciferols
Treatment 1- 400,000 IU
• Ergocalciferols
Treatment 2- 800,000 IU

Locations

Country	Name	City	State
United States	Walter Reed National Military Medical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Walter Reed National Military Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	serum 25-hydroxy-vitamin D level		12 weeks